NEW YORK, Nov. 5 – Incyte Genomics said Monday that it had licensed its main microarray and gene expression patents to Agilent Technologies, a manufacturer of printed DNA microarrays.
Under the terms of the licensing agreements, Incyte will provide Agilent with its patents for nucleic acid linear amplification, the manufacture and use of DNA microarrays, and the use of gene expression arrays in cancer research and diagnosis.
Incyte has also exclusively licensed to Agilent its patent portfolio for inkjet array manufacture, including patents for in situ synthesis of nucleic acid microarrays.
"We are pleased to add the Incyte patents to the already extensive portfolio of Agilent patents and patent licenses," Barney Saunders, vice president and general manager of Agilent's Bio-Research Solutions, said in a statement.
"These patents will consolidate and strengthen Agilent's position as a major manufacturer of printed DNA microarrays and as a supplier of reagents and kits for sample preparation," Saunders said.
Financial terms of the deal were not disclosed.
In January, Agilent opened a 15,000-square-foot DNA microarray production facility as part of its efforts to expand its microarray manufacturing program, which included plans to ship over one million microarrays per year by 2002.
As part of that effort, Agilent also previously signed a deal for access to Incyte’s cDNA clones and its Lifeseq data for use on the company’s off-the-shelf arrays.
Both Agilent and Incyte are based in Palo Alto, Calif.